Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 7/2007

01-05-2007 | Original Article

Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile

Authors: Sana Al-Mutairi, Adel Al-Awadhi, Raj Raghupathy, Hanaa Al-Khawari, Prio Sada, Adeebah Al-Herz, Parvez Rawoot

Published in: Rheumatology International | Issue 7/2007

Login to get access

Abstract

Objectives

The literature on cytokine response in systemic lupus erythematosus (SLE) is confusing. It is possible that different disease phenotypes have different cytokine profiles. Our aim was to examine the levels of selected pro-inflammatory and anti-inflammatory cytokines in SLE patients with and without pulmonary involvement.

Methods and subjects

Patients with SLE were interviewed and were subjected to the pulmonary function test and high-resolution computed tomography studies. Serum levels of interleukin (IL)-6, IL-8, IL-10, Il-12, interferon (IFN) γ, and tumor necrosis factor (TNF) α were estimated by enzyme-linked immunosorbent assay.

Results

Forty-nine of the 61 SLE patients had pulmonary involvement. Median levels of IL-8, IFNγ, and TNFα were significantly higher in the pulmonary group as compared to the non-pulmonary group (p = 0.027, 0.027 and 0.002, respectively). Ratios of pro-inflammatory cytokines to anti-inflammatory cytokines were higher in the pulmonary group as compared to the non-pulmonary group as well as in the pulmonary restrictive subgroup compared to the obstructive subgroup.

Conclusion

Lupus patients with pulmonary involvement have a stronger pro-inflammatory cytokine bias than those without pulmonary involvement.
Literature
1.
2.
Lauwerys BR, Houssiau FA (2003) Involvement of cytokines in the pathogenesis of systemic lupus erythematosus. In: Santamaria P (ed) Cytokines and chemokines in autoimmune disease. Plenum Publishers, New York, pp 237–251
3.
4.
Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243–251PubMedCrossRef
5.
Tam EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRef
6.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for Lupus patients. Arthritis Rheum 35:630–640PubMedCrossRef
7.
Burney PGJ, Luczynska C, Chinn S, Jarvis D (1994) The European Community Respiratory Health Survey. Eur Respir J 7:954–960PubMed
8.
The European Community Respiratory Health Survey “Medicine and Health” (1994) EC Directorate General XIII. Office for Official Publications, Luxemburg
9.
Medical Research Council Respiratory Symptoms Questionnaire (1976) The Council, London
10.
Toren K, Brisman J, Jarvholm B (1993) Asthma and asthma-like symptoms in adults assessed by questionnaires: a literature review. Chest 104:600–608PubMed
11.
Burney PGJ, Laitinen LA, Predrizet S, Huckauf H, Tattersfield AE, Chinn S, Poisson N, Heeren A, Britton JR, Jones T (1989) Validity and repeatability of the IUATLD (1984) bronchial symptoms questionnaire: an international comparison. Eur Respir J 2:940–945PubMed
12.
Burney PGJ, Chinn S, Britton JR, Tattersfield AE, Papacosta AO (1989) What symptoms predict the bronchial response to histamine? Evaluation in a community survey of the bronchial symptoms questionnaire (1984) of the International Union Against Tuberculosis and Lung Disease. Int J Epidemiol 18:165–173PubMedCrossRef
13.
Burney PGJ, Papacosta AO, Withey CH, Colley JRT, Holland WW (1991) Hospital admission rates and the prevalence of asthma symptoms in 20 local authority districts. Thorax 46:574–579PubMedCrossRef
14.
Jarvis D, Lai E, Luczynska C, Chinn S, Burney P (1994) Prevalence of asthma and asthma-like symptoms in young adults living in three East Anglian towns. Br J General Patrice 44:493–497
15.
Sunyer J, Basagana X, Burney P, Anto JM (2000) International assessment of the internal consistency of respiratory symptoms. European Community Respiratory Health Study (ECRHS). Am J Resp Crit Care Med 162:930–935PubMed
16.
Abramson M, Matheson M, Wharton C, Sim M, Walters HE (2002) Prevalence of respiratory symptoms related to chronic obstructive pulmonary disease and asthma among middle aged and older adults. Respirology 7:325–331PubMedCrossRef
17.
National Institute for Clinical Excellence (NICE) (2004) Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 (Suppl 1):1–232
18.
Grassi M, Villani S, Marinoni A, for ECRHS Group (2001) Classification methods for the identification of “case” in epidemiological diagnosis of asthma. Eur J Epidemiol 17:19–29PubMedCrossRef
19.
Standardization of Spirometry, 1994 Update (1995) American Thoracic Society. Am J Respir Crit Care Med 152:1107–1136
20.
British Thoracic Society, Scottish Intercollegiate Guideline Network (2003) British Guidelines on the management of asthma. Thorax 58(Suppl 1):1–94
21.
American Thoracic Society (1991) Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 144:1202–1216
22.
Morimoto S, Tokano Y, Kaneko H, Nowaza K, Amano H, Hashimoto H (2001) The increased interleukin-13 in patients with systemic lupus erythematosus: relation to other Th1-, Th2-related cytokines and clinical findings. Autoimmunity 34:19–25PubMedCrossRef
23.
Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S (2003) Serum concentration of CXC chemokines interleukin 8 a growth-related oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 30:1524–1528PubMed
24.
Yoshio T, Masuyama JI, Kohda N, Hirata D, Sato H, Iwamoto M, Mimori A, Takeda A, Minota S, Kano S (1997) Association of interleukin-6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol 24:489–495PubMed
25.
Cross JT, Benton HP (1999) The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 48:255–261PubMedCrossRef
26.
27.
Romognani S (2000) T-cell subsets (Th1 versus Th2). Ann Aller Asthma Immunol 85:9–18
28.
Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D (2000) Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790–800PubMedCrossRef
29.
Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Yakasaki Y, Hashimoto H (1999) Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 116:169–173PubMedCrossRef
30.
Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, Stepien H (2002) Pro-inflammatory interferon-γ-inducing monokines (interleukin-12, interleukin-18, interleukin-15)-serum profile in patients with systemic lupus erythematosus. Eur Cytokine Network 13:364–368
31.
Wong CK, Ho CY, Li EK, Lam CWK (2000) Elevation of pro-inflammatory cytokine (IL-18, IL-17, IL-12) and Th2-cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9:589–593PubMedCrossRef
32.
Liu TF, Jones BM (1994) Impaired production of IL-12 in systemic lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFNγ and negatively with disease activity in SLE. Cytokines 10:148–153CrossRef
33.
Liu TF, Jones BM, Wong RW, Srivastava G (1999) Impaired production of IL-12 in systemic lupus erythematosus. III. Deficient IL-12 p40 gene expression and cross-regulation of IL-12, IL-10 and IFN-gamma gene expression. Cytokines 11:805–811CrossRef
34.
Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Oht K, Trinchieri G (1998) Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 41:838–844PubMedCrossRef
35.
Spadaro A, Scrivo R, Rinaldi T, Riccieri V, Sili Scavalli A, Taccari E, Valesini G (2002) The role of interleukin-12 in immune-mediated rheumatic diseases. Reumatismo 54:113–121PubMed
36.
Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNF alpha, p55 srTNF alpha, p75 srTNF alpha, srIL-12 alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22PubMedCrossRef
37.
Nakajima A, Hirose S, Yagita H, Okumura K (1997) Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 158:1466–1472PubMed
38.
Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, Ragnaud JM, Leng B, Moreau JF (1999) Th1 (IL-2, interferon-gamma IFN-gamma) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 115:189–195PubMedCrossRef
39.
Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM (1997) Low levels of interleukin-1 receptor antagonist coincides with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 36:1283–1289PubMedCrossRef
40.
Holcombe RF, Baethge BA, Wolf RE, Betzing KW, Stewart RM, Hal VC, Fukuda M (1994) Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus 3:97–102PubMed
41.
Hsieh SC, Tsai CY, Sun KH, Yu HS, Tsai ST, Wang JC, Tsai YY, Han SH, Yu CL (1994) Decreased spontaneous and lipopolysaccharide stimulated production of interleukin 8 by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Clin Exp Immunol 12:627–633
42.
Hsieh SC, Yu HS, Lin WW, Sun KH, Tsai CY, Huang DF, Tsai YY, Yu CL (2003) Anti-SSB/La is one of the antineutrophil antibodies responsible for neutropenia and functional impairment of polymorphonuclear neutrophils in patients with systemic lupus erythematosus. Clin Exp Immunol 131:506–516PubMedCrossRef
43.
Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147:117–123PubMed
44.
Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S (1993) Cytokine profiles in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13:58–67PubMedCrossRef
45.
Barcellini W, Rizzardi GP, Borghi MO, Nicoletti F, Fain C, Del-Papa N, Meroni PL (1996) In vitro type-1 and type-2 cytokines production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 5:139–145PubMed
46.
Emilie D, Llorente L, Galanaud P (1996) Cytokines and lupus. Ann Med Intern (Paris) 147:480–484
47.
Lauwerys BR, Van Snick J, Houssiau FA (2002) Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 11:384–387PubMedCrossRef
48.
Abal At, Nair MGP, Behbehani NA, Sharma PN (2001) Hospital admissions and death rates from asthma in Kuwait during pre- and post-Gulf War periods. Ann Aller Asthma Immunol 86:465–468CrossRef
49.
Behbehani NA, Abal A, Syabbalo NC, Azeem AA, Shareef E, Al-Momen J (2000) Prevalence of asthma, allergic rhinitis, and eczema in 13- to 14-year-old children in Kuwait: an ISAAC study. Ann Allergy Asthma Immunol 85:58–63PubMed
Metadata
Title
Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile
Authors
Sana Al-Mutairi
Adel Al-Awadhi
Raj Raghupathy
Hanaa Al-Khawari
Prio Sada
Adeebah Al-Herz
Parvez Rawoot
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0268-3

Other articles of this Issue 7/2007

Rheumatology International 7/2007 Go to the issue

Case Report

Case report of a patient with osteopoikilosis

Case Report

Spontaneous pneumomediastinum and subcutaneous emphysema in systemic sclerosis

Letter to the editor

An unusual case of Wegener’s granulomatosis developing with glomerulonephritis as an initial manifestation

Original Article

Correlation between Yersinia enterocolitica and type I collagen reactivity in patients with arthropathies

Original Article

A single intravenous dose of prednisolone induces phosphatidylserine externalization, loss of surface marker expression and a 24-h net increase in human peripheral blood lymphocytes ex vivo

Original Article

Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits